Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Andremacon S R L operates a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action currently active. This indicates a focused effort to protect a specific biological or pharmaceutical innovation through the patent office. The current level of activity suggests that the company is in a critical stage of securing rights for its core technology.
The prosecution is handled by a distinct examiner and 1 distinct art unit. This suggests that the company's current filings fall within a specialized technical category. REGINA M DEBERRY is the busiest examiner for the portfolio, currently managing the busiest examiner pending office action. This examiner is the only official currently reviewing the company's pending claims, which provides an opportunity for a consistent and focused technical dialogue.
For the legal team, the presence of the distinct art unit simplifies the procedural landscape. Because there is 1 pending office action, the prosecution strategy is entirely centered on the feedback from REGINA M DEBERRY. This allows for a concentrated response to any rejections within the Biotechnology & Pharmaceuticals sector, ensuring that the technical arguments are specifically tailored to the examiner's requirements and the standards of the assigned art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEBERRY, REGINA M | 1 | 50.2% | +30.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17367666 | USE OF NEGATIVE FUNCTIONAL MODULATORS OF ERYTHROPOIETIN FOR THERAPY | DEBERRY, REGINA M | 46d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17367666 | USE OF NEGATIVE FUNCTIONAL MODULATORS OF ERYTHROPOIETIN FOR THERAPY | DEBERRY, REGINA M | 46d overdue |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17367666 | USE OF NEGATIVE FUNCTIONAL MODULATORS OF ERYTHROPOIETIN FOR THERAPY | DEBERRY, REGINA M | 1647 | §102§103§112 | Non-Final OA | 46d overdue | Pending | Jul 06, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAndremacon S R L has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Regina M Deberry has the most, with 1 of Andremacon S R L's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
